FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059370937> ?p ?o ?g. }

• W2059370937 endingPage "954.e1" @default.
• W2059370937 startingPage "947" @default.
• W2059370937 abstract "Purpose To evaluate the efficacy of photodynamic therapy with verteporfin with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Design Retrospective case study. Methods This study included 29 treatment-naïve patients with polypoidal choroidal vasculopathy followed up for 12 months after the first combined therapy. Patients received 1.25 mg intravitreal bevacizumab 1 week before photodynamic therapy with verteporfin. The main outcomes measures were visual acuity and the number of required retreatments. Results The mean best-corrected visual acuity (BCVA) level was 0.25 at baseline and 0.31, 0.39, 0.44, 0.44, and 0.45 at 1, 3, 6, 9, and 12 months after treatment, respectively. A significant (P< .01) improvement in the mean BCVA was observed at 3, 6, 9, and 12 months after combined therapy. At 12 months, the mean improvement in BCVA from baseline was 2.69 lines; the BCVA improved in 15 eyes (51.7%) by 3 lines or more, was stable in 13 eyes (44.8%), and decreased in 1 eye (3%) because of a massive subretinal hemorrhage 7 months after the first treatment. Eighteen eyes (62%) required 1 combined treatment during follow-up. Polypoidal lesions recurred in 6 eyes (21%). An abnormal branching vascular network persisted in all eyes. The mean number of treatments with combined therapy averaged 1.59. No complications, including endophthalmitis, uveitis, or ocular hypertension, developed. Conclusions Combined treatment consisting of photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy seemed to be effective for improving visual acuity and reducing retreatment rates and complications. Further study is needed to determine the long-term clinical results. To evaluate the efficacy of photodynamic therapy with verteporfin with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Retrospective case study. This study included 29 treatment-naïve patients with polypoidal choroidal vasculopathy followed up for 12 months after the first combined therapy. Patients received 1.25 mg intravitreal bevacizumab 1 week before photodynamic therapy with verteporfin. The main outcomes measures were visual acuity and the number of required retreatments. The mean best-corrected visual acuity (BCVA) level was 0.25 at baseline and 0.31, 0.39, 0.44, 0.44, and 0.45 at 1, 3, 6, 9, and 12 months after treatment, respectively. A significant (P< .01) improvement in the mean BCVA was observed at 3, 6, 9, and 12 months after combined therapy. At 12 months, the mean improvement in BCVA from baseline was 2.69 lines; the BCVA improved in 15 eyes (51.7%) by 3 lines or more, was stable in 13 eyes (44.8%), and decreased in 1 eye (3%) because of a massive subretinal hemorrhage 7 months after the first treatment. Eighteen eyes (62%) required 1 combined treatment during follow-up. Polypoidal lesions recurred in 6 eyes (21%). An abnormal branching vascular network persisted in all eyes. The mean number of treatments with combined therapy averaged 1.59. No complications, including endophthalmitis, uveitis, or ocular hypertension, developed. Combined treatment consisting of photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy seemed to be effective for improving visual acuity and reducing retreatment rates and complications. Further study is needed to determine the long-term clinical results." @default.
• W2059370937 created "2016-06-24" @default.
• W2059370937 creator A5003897225 @default.
• W2059370937 creator A5040679158 @default.
• W2059370937 creator A5043759410 @default.
• W2059370937 creator A5080805669 @default.
• W2059370937 date "2010-06-01" @default.
• W2059370937 modified "2023-09-24" @default.
• W2059370937 title "Combined Photodynamic Therapy With Verteporfin and Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy" @default.
• W2059370937 cites W1481983591 @default.
• W2059370937 cites W1768895213 @default.
• W2059370937 cites W193593035 @default.
• W2059370937 cites W1968609549 @default.
• W2059370937 cites W1971987022 @default.
• W2059370937 cites W1974272630 @default.
• W2059370937 cites W1979874741 @default.
• W2059370937 cites W1987699263 @default.
• W2059370937 cites W1987722557 @default.
• W2059370937 cites W1988233478 @default.
• W2059370937 cites W1991843154 @default.
• W2059370937 cites W1995708259 @default.
• W2059370937 cites W1996044788 @default.
• W2059370937 cites W2006202974 @default.
• W2059370937 cites W2023523208 @default.
• W2059370937 cites W2033245558 @default.
• W2059370937 cites W2036516882 @default.
• W2059370937 cites W2036687136 @default.
• W2059370937 cites W2039936409 @default.
• W2059370937 cites W2045317893 @default.
• W2059370937 cites W2051842051 @default.
• W2059370937 cites W2054180058 @default.
• W2059370937 cites W2054334822 @default.
• W2059370937 cites W2055522471 @default.
• W2059370937 cites W2062478098 @default.
• W2059370937 cites W2074375736 @default.
• W2059370937 cites W2080131028 @default.
• W2059370937 cites W2080591818 @default.
• W2059370937 cites W2081233482 @default.
• W2059370937 cites W2106178997 @default.
• W2059370937 cites W2112387863 @default.
• W2059370937 cites W2122761637 @default.
• W2059370937 cites W2130645650 @default.
• W2059370937 cites W2142979206 @default.
• W2059370937 cites W2167622011 @default.
• W2059370937 cites W2233259956 @default.
• W2059370937 cites W4249438516 @default.
• W2059370937 doi "https://doi.org/10.1016/j.ajo.2009.12.038" @default.
• W2059370937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20346441" @default.
• W2059370937 hasPublicationYear "2010" @default.
• W2059370937 type Work @default.
• W2059370937 sameAs 2059370937 @default.
• W2059370937 citedByCount "66" @default.
• W2059370937 countsByYear W20593709372012 @default.
• W2059370937 countsByYear W20593709372013 @default.
• W2059370937 countsByYear W20593709372014 @default.
• W2059370937 countsByYear W20593709372015 @default.
• W2059370937 countsByYear W20593709372016 @default.
• W2059370937 countsByYear W20593709372017 @default.
• W2059370937 countsByYear W20593709372018 @default.
• W2059370937 countsByYear W20593709372019 @default.
• W2059370937 countsByYear W20593709372020 @default.
• W2059370937 countsByYear W20593709372021 @default.
• W2059370937 countsByYear W20593709372023 @default.
• W2059370937 crossrefType "journal-article" @default.
• W2059370937 hasAuthorship W2059370937A5003897225 @default.
• W2059370937 hasAuthorship W2059370937A5040679158 @default.
• W2059370937 hasAuthorship W2059370937A5043759410 @default.
• W2059370937 hasAuthorship W2059370937A5080805669 @default.
• W2059370937 hasConcept C118487528 @default.
• W2059370937 hasConcept C141071460 @default.
• W2059370937 hasConcept C178790620 @default.
• W2059370937 hasConcept C185592680 @default.
• W2059370937 hasConcept C2776694085 @default.
• W2059370937 hasConcept C2777235844 @default.
• W2059370937 hasConcept C2777802072 @default.
• W2059370937 hasConcept C2778257484 @default.
• W2059370937 hasConcept C2781148688 @default.
• W2059370937 hasConcept C2781323092 @default.
• W2059370937 hasConcept C2781359195 @default.
• W2059370937 hasConcept C71924100 @default.
• W2059370937 hasConceptScore W2059370937C118487528 @default.
• W2059370937 hasConceptScore W2059370937C141071460 @default.
• W2059370937 hasConceptScore W2059370937C178790620 @default.
• W2059370937 hasConceptScore W2059370937C185592680 @default.
• W2059370937 hasConceptScore W2059370937C2776694085 @default.
• W2059370937 hasConceptScore W2059370937C2777235844 @default.
• W2059370937 hasConceptScore W2059370937C2777802072 @default.
• W2059370937 hasConceptScore W2059370937C2778257484 @default.
• W2059370937 hasConceptScore W2059370937C2781148688 @default.
• W2059370937 hasConceptScore W2059370937C2781323092 @default.
• W2059370937 hasConceptScore W2059370937C2781359195 @default.
• W2059370937 hasConceptScore W2059370937C71924100 @default.
• W2059370937 hasIssue "6" @default.
• W2059370937 hasLocation W20593709371 @default.
• W2059370937 hasLocation W20593709372 @default.
• W2059370937 hasOpenAccess W2059370937 @default.
• W2059370937 hasPrimaryLocation W20593709371 @default.
• W2059370937 hasRelatedWork W1956703773 @default.

• next